All Stories

  1. EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma

    Article • Leukemia, August 2023, Springer Science + Business Media

    Dr Jerome Moreaux

  2. S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability in multiple myeloma

    Article • Haematologica, July 2023, Ferrata Storti Foundation (Haematologica)

    Dr Jerome Moreaux

  3. MRE11 and TREX1 control senescence by coordinating replication stress and interferon signaling

    Article • July 2023, Research Square

    Dr Jerome Moreaux

  4. Var∣Decrypt: a novel and user-friendly tool to explore and prioritize variants in whole-exome sequencing data

    Article • Epigenetics & Chromatin, June 2023, Springer Science + Business Media

    Dr Jerome Moreaux

  5. 3-O sulfation of syndecan-1 mediated by the sulfotransferase HS3ST3a1 enhances myeloma aggressiveness

    Article • Matrix Biology, June 2023, Elsevier

    Dr Jerome Moreaux

  6. LAIR1, an ITIM-Containing Receptor Involved in Immune Disorders and in Hematological Neoplasms

    Article • International Journal of Molecular Sciences, December 2022, MDPI AG

    Dr Jerome Moreaux

  7. The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance

    Article • Frontiers in Immunology, December 2022, Frontiers

    Dr Jerome Moreaux

  8. Var|Decrypt: a novel and user-friendly tool to explore and prioritize variants in whole-exome sequencing data

    Article • September 2022, Cold Spring Harbor Laboratory Press

    Dr Jerome Moreaux

  9. Inhibition of the Protein Arginine Methyltransferase PRMT5 in High-Risk Multiple Myeloma as a Novel Treatment Approach

    Article • Frontiers in Cell and Developmental Biology, June 2022, Frontiers

    Dr Jerome Moreaux

  10. Single-hit genome edition for expression of single-chain immunoglobulins by edited B cells

    Article • June 2022, Cold Spring Harbor Laboratory Press

    Dr Jerome Moreaux

  11. PIM2 kinase has a pivotal role in plasmablast generation and plasma cell survival, opening up novel treatment options in myeloma

    Article • Blood, April 2022, American Society of Hematology

    Dr Jerome Moreaux

  12. Targeting Cellular Iron Homeostasis with Ironomycin in Diffuse Large B-cell Lymphoma

    Article • Cancer Research, March 2022, American Association for Cancer Research (AACR)

    Dr Jerome Moreaux

  13. The NADPH oxidase NOX2 is a marker of adverse prognosis involved in chemoresistance of acute myeloid leukemias

    Article • Haematologica, February 2022, Ferrata Storti Foundation (Haematologica)

    Dr Jerome Moreaux

  14. Comprehensive characterization of the epigenetic landscape in Multiple Myeloma

    Article • Theranostics, January 2022, Ivyspring International Publisher

    Dr Jerome Moreaux

  15. Angiogenic factors could help us to define patients obtaining complete response with undetectable minimal residual disease in untreated CLL patients treated by FCR: results from the CLL2010FMP, a FILO study

    Article • Leukemia & Lymphoma, November 2021, Taylor & Francis

    Dr Jerome Moreaux

  16. The microenvironment of DLBCL is characterized by noncanonical macrophages recruited by tumor-derived CCL5

    Article • Blood Advances, October 2021, American Society of Hematology

    Dr Jerome Moreaux

  17. RNA-Sequencing-Based Transcriptomic Score with Prognostic and Theranostic Values in Multiple Myeloma

    Article • Journal of Personalized Medicine, September 2021, MDPI AG

    Dr Jerome Moreaux

  18. Targeting the methyltransferase SETD8 impairs tumor cell survival and overcomes drug resistance independently of p53 status in multiple myeloma

    Article • Clinical Epigenetics, September 2021, Springer Science + Business Media

    Dr Jerome Moreaux

  19. Transcription/Replication Conflicts in Tumorigenesis and Their Potential Role as Novel Therapeutic Targets in Multiple Myeloma

    Article • Cancers, July 2021, MDPI AG

    Dr Jerome Moreaux

  20. Clinical Correlations of Polycomb Repressive Complex 2 in Different Tumor Types

    Article • Cancers, June 2021, MDPI AG

    Dr Jerome Moreaux

  21. Discovery of Candidate DNA Methylation Cancer Driver Genes

    Article • Cancer Discovery, May 2021, American Association for Cancer Research (AACR)

    Dr Jerome Moreaux

  22. G9a/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor–mediated cell death

    Article • Blood Advances, May 2021, American Society of Hematology

    Dr Jerome Moreaux

  23. RNA-sequencing data-driven dissection of human plasma cell differentiation reveals new potential transcription regulators

    Article • Leukemia, April 2021, Springer Science + Business Media

    Dr Jerome Moreaux

  24. Immunotherapy perspectives in the new era of B-cell editing

    Article • Blood Advances, March 2021, American Society of Hematology

    Dr Jerome Moreaux

  25. The NADPH oxidase NOX2 is a marker of adverse prognosis involved in chemoresistance of Acute Myeloid Leukemias

    Article • March 2021, Cold Spring Harbor Laboratory Press

    Dr Jerome Moreaux

  26. The origin of preplasmablastic cells

    Article • Blood, March 2021, American Society of Hematology

    Dr Jerome Moreaux

  27. Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma

    Article • Exploration of Targeted Anti-tumor Therapy, February 2021, Open Exploration Publishing

    Dr Jerome Moreaux

  28. Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma

    Article • Exploration of Targeted Anti-tumor Therapy, February 2021, Open Exploration Publishing

    Dr Jerome Moreaux

  29. Role of Polycomb Complexes in Normal and Malignant Plasma Cells

    Article • International Journal of Molecular Sciences, October 2020, MDPI AG

    Dr Jerome Moreaux

  30. DNA Repair Expression Profiling to Identify High-Risk Cytogenetically Normal Acute Myeloid Leukemia and Define New Therapeutic Targets

    Article • Cancers, October 2020, MDPI AG

    Dr Jerome Moreaux

  31. A Retrospective Comparison of DLI and gDLI for Post-Transplant Treatment

    Article • Journal of Clinical Medicine, July 2020, MDPI AG

    Dr Jerome Moreaux

  32. Correction to: Characterization of immortalized human islet stromal cells reveals a MSC-like profile with pancreatic features

    Article • Stem Cell Research & Therapy, May 2020, Springer Science + Business Media

    Dr Jerome Moreaux

  33. Characterization of immortalized human islet stromal cells reveals a MSC-like profile with pancreatic features

    Article • Stem Cell Research & Therapy, April 2020, Springer Science + Business Media

    Dr Jerome Moreaux

  34. Dihydropyrimidinase protects from DNA replication stress caused by cytotoxic metabolites

    Article • Nucleic Acids Research, December 2019, Oxford University Press (OUP)

    Dr Jerome Moreaux

  35. Anticorps anti-CD38 dans le myélome multiple

    Article • médecine/sciences, December 2019, EDP Sciences

    Dr Jerome Moreaux

  36. Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma

    Article • Blood Cancer Journal, November 2019, Springer Science + Business Media

    Dr Jerome Moreaux

  37. Targeting the methyltransferase SETD8 impairs tumor cell survival and overcomes drug resistance independently of p53 status in multiple myeloma

    Article • September 2019, Cold Spring Harbor Laboratory Press

    Dr Jerome Moreaux

  38. Treatment May Be Harmful: Mechanisms/Prediction/Prevention of Drug-Induced DNA Damage and Repair in Multiple Myeloma

    Article • Frontiers in Genetics, September 2019, Frontiers

    Dr Jerome Moreaux

  39. Phenotypic Characterization of Diffuse Large B-Cell Lymphoma Cells and Prognostic Impact

    Article • Journal of Clinical Medicine, July 2019, MDPI AG

    Dr Jerome Moreaux

  40. Kinome expression profiling to target new therapeutic avenues in multiple myeloma

    Article • Haematologica, July 2019, Ferrata Storti Foundation (Haematologica)

    Dr Jerome Moreaux

  41. Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial

    Article • Journal of Hematology & Oncology, June 2019, Springer Science + Business Media

    Dr Jerome Moreaux

  42. The hydroxymethylome of multiple myeloma identifies FAM72D as a 1q21 marker linked to proliferation

    Article • Haematologica, June 2019, Ferrata Storti Foundation (Haematologica)

    Dr Jerome Moreaux

  43. Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (ATR) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer

    Article • Cancer Research, June 2019, American Association for Cancer Research (AACR)

    Dr Jerome Moreaux

  44. The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma

    Article • British Journal of Cancer, May 2019, Springer Science + Business Media

    Dr Jerome Moreaux

  45. Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells

    Article • Cancers, March 2019, MDPI AG

    Dr Jerome Moreaux

  46. Overexpression of Claspin and Timeless protects cancer cells from replication stress in a checkpoint-independent manner

    Article • Nature Communications, February 2019, Springer Science + Business Media

    Dr Jerome Moreaux

  47. EZH2 is overexpressed in transitional preplasmablasts and is involved in human plasma cell differentiation

    Article • Leukemia, February 2019, Springer Science + Business Media

    Dr Jerome Moreaux

  48. Myeloid-derived suppressor cells induce multiple myeloma cell survival by activating the AMPK pathway

    Article • Cancer Letters, February 2019, Elsevier

    Dr Jerome Moreaux

  49. In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

    Article • Journal of Visualized Experiments, January 2019, MyJove Corporation

    Dr Jerome Moreaux

  50. Characterization of the mutational landscape in multiple myeloma cell lines

    Article • Theranostics, January 2019, Ivyspring International Publisher

    Dr Jerome Moreaux

  51. BrdU incorporation in multiparameter flow cytometry: A new cell cycle assessment approach in multiple myeloma

    Article • Cytometry Part B Clinical Cytometry, November 2018, Wiley

    Dr Jerome Moreaux

  52. PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs

    Article • Clinical Epigenetics, October 2018, Springer Science + Business Media

    Dr Jerome Moreaux

  53. Dihydropyrimidinase protects from DNA replication stress caused by cytotoxic metabolites.

    Article • September 2018, Cold Spring Harbor Laboratory Press

    Dr Jerome Moreaux

  54. Physiological and druggable skipping of immunoglobulin variable exons in plasma cells

    Article • Cellular and Molecular Immunology, August 2018, Springer Science + Business Media

    Dr Jerome Moreaux

  55. Rôle de EZH2 comme biomarqueur dans le traitement personnalisé du myélome multiple

    Article • Bulletin du Cancer, July 2018, Elsevier

    Dr Jerome Moreaux

  56. Tumor-associated neutrophils correlate with poor prognosis in diffuse large B-cell lymphoma patients

    Article • Blood Cancer Journal, July 2018, Springer Science + Business Media

    Dr Jerome Moreaux

  57. GEP-based EpiScore predicts survival in patients with diffuse large B cell lymphoma

    Article • Oncotarget, March 2018, Impact Journals, LLC

    Dr Jerome Moreaux

  58. DNMTi/HDACi induces reprogramming of myeloma cells in the direction of normal plasma cells

    Article • British Journal of Cancer, March 2018, Springer Science + Business Media

    Dr Jerome Moreaux

  59. Analysis of Global Gene Expression Profiles

    Article • January 2018, Springer Science + Business Media

    Dr Jerome Moreaux

  60. Loss of RASSF4 Promotes RAS-Driven Malignant Progression in MM

    Article • Cancer Research, December 2017, American Association for Cancer Research (AACR)

    Dr Jerome Moreaux

  61. CD24, CD27, CD36 and CD302 gene expression predict outcome in patients with multiple myeloma

    Article • Oncotarget, October 2017, Impact Journals, LLC

    Dr Jerome Moreaux

  62. Automated and simplified identification of normal and abnormal plasma cells in Multiple Myeloma by flow cytometry

    Article • Cytometry Part B Clinical Cytometry, September 2017, Wiley

    Dr Jerome Moreaux

  63. Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion

    Article • Cancer Immunology Research, September 2017, American Association for Cancer Research (AACR)

    Dr Jerome Moreaux

  64. Characterization of human FCRL4-positive B cells

    Article • PLoS ONE, June 2017, PLOS

    Dr Jerome Moreaux

  65. Hypoxia favors the generation of human plasma cells

    Article • Cell Cycle, May 2017, Taylor & Francis

    Dr Jerome Moreaux

  66. Global miRNA expression analysis identifies novel key regulators of plasma cell differentiation and malignant plasma cell

    Article • Nucleic Acids Research, April 2017, Oxford University Press (OUP)

    Dr Jerome Moreaux

  67. RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma

    Article • Leukemia, February 2017, Nature

    Dr Jerome Moreaux

  68. Forced KLF4 expression increases the generation of mature plasma cells and uncovers a network linked with plasma cell stage

    Article • Cell Cycle, May 2016, Taylor & Francis

    Dr Jerome Moreaux

  69. Differential effects of lenalidomide during plasma cell differentiation

    Article • Oncotarget, May 2016, Impact Journals, LLC

    Dr Jerome Moreaux

  70. RECQ helicases are deregulated in hematological malignancies in association with a prognostic value

    Article • Biomarker Research, February 2016, Springer Science + Business Media

    Dr Jerome Moreaux

  71. Identifying high-risk adult AML patients: epigenetic and genetic risk factors and their implications for therapy

    Article • Expert Review of Hematology, February 2016, Taylor & Francis

    Dr Jerome Moreaux

  72. Chetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myeloma

    Article • British Journal of Cancer, February 2016, Nature

    Dr Jerome Moreaux

  73. Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells

    Article • Oncotarget, January 2016, Impact Journals, LLC

    Dr Jerome Moreaux

  74. miRNAs in multiple myeloma – a survival relevant complex regulator of gene expression

    Article • Oncotarget, November 2015, Impact Journals, LLC

    Dr Jerome Moreaux

  75. EZH2 in normal hematopoiesis and hematological malignancies

    Article • Oncotarget, October 2015, Impact Journals, LLC

    Dr Jerome Moreaux

  76. Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma

    Article • Blood Cancer Journal, August 2015, Nature

    Dr Jerome Moreaux

  77. Drug metabolism and clearance system in tumor cells of patients with multiple myeloma

    Article • Oncotarget, March 2015, Impact Journals, LLC

    Dr Jerome Moreaux

  78. In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma

    Article • Oncotarget, February 2015, Impact Journals, LLC

    Dr Jerome Moreaux

  79. Expression and role of RIP140/NRIP1 in chronic lymphocytic leukemia

    Article • Journal of Hematology & Oncology, January 2015, Springer Science + Business Media

    Dr Jerome Moreaux

  80. SNaPshot as a Valuable Option for the Identification of Mutations in Myeloma

    Article • EBioMedicine, January 2015, Elsevier

    Dr Jerome Moreaux

  81. The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cells

    Article • Haematologica, December 2014, Ferrata Storti Foundation (Haematologica)

    Dr Jerome Moreaux

  82. DNA repair in diffuse large B-cell lymphoma: a molecular portrait

    Article • British Journal of Haematology, November 2014, Wiley

    Dr Jerome Moreaux

  83. Identification and characterization of new Leishmania promastigote surface antigens, LaPSA-38S and LiPSA-50S, as major immunodominant excreted/secreted components of L. amazonensis and L. infantum

    Article • Infection Genetics and Evolution, June 2014, Elsevier

    Dr Jerome Moreaux

  84. A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategy

    Article • Oncotarget, May 2014, Impact Journals, LLC

    Dr Jerome Moreaux

  85. Identification of a 20-Gene Expression-Based Risk Score as a Predictor of Clinical Outcome in Chronic Lymphocytic Leukemia Patients

    Article • BioMed Research International, January 2014, Hindawi Publishing Corporation

    Dr Jerome Moreaux

  86. The Glycome of Normal and Malignant Plasma Cells

    Article • PLoS ONE, December 2013, PLOS

    Dr Jerome Moreaux

  87. DNA methylation score is predictive of myeloma cell sensitivity to 5-azacitidine

    Article • British Journal of Haematology, November 2013, Wiley

    Dr Jerome Moreaux

  88. DNA repair pathways in human multiple myeloma

    Article • Cell Cycle, September 2013, Taylor & Francis

    Dr Philippe Pasero, Dr Jerome Moreaux

  89. Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors

    Article • British Journal of Cancer, July 2013, Nature

    Dr Jerome Moreaux

  90. Nucleotide excision DNA repair pathway as a therapeutic target in patients with high-risk diffuse large B cell lymphoma

    Article • Cell Cycle, June 2013, Taylor & Francis

    Dr Jerome Moreaux

  91. Inhibition of DEPDC1A, a Bad Prognostic Marker in Multiple Myeloma, Delays Growth and Induces Mature Plasma Cell Markers in Malignant Plasma Cells

    Article • PLoS ONE, April 2013, PLOS

    Dr Jerome Moreaux

  92. Kruppel-like factor 4 blocks tumor cell proliferation and promotes drug resistance in multiple myeloma

    Article • Haematologica, April 2013, Ferrata Storti Foundation (Haematologica)

    Dr Jerome Moreaux

  93. STEAP1 is overexpressed in cancers: A promising therapeutic target

    Article • Biochemical and Biophysical Research Communications, December 2012, Elsevier

    Dr Jerome Moreaux

  94. Gene expression-based risk score in diffuse large B-cell lymphoma

    Article • Oncotarget, December 2012, Impact Journals, LLC

    Dr Jerome Moreaux

  95. Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma?

    Article • Oncotarget, November 2012, Impact Journals, LLC

    Dr Jerome Moreaux

  96. Growth Factors in Multiple Myeloma

    Article • October 2012, Springer Science + Business Media

    Dr Jerome Moreaux

  97. Development of Gene Expression-Based Score to Predict Sensitivity of Multiple Myeloma Cells to DNA Methylation Inhibitors

    Article • Molecular Cancer Therapeutics, October 2012, American Association for Cancer Research (AACR)

    Dr Jerome Moreaux

  98. Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients

    Article • Oncotarget, August 2012, Impact Journals, LLC

    Dr Jerome Moreaux

  99. Identification of Pluripotent and Adult Stem Cell Genes Unrelated to Cell Cycle and Associated with Poor Prognosis in Multiple Myeloma

    Article • PLoS ONE, July 2012, PLOS

    Dr Jerome Moreaux

  100. Clinical and prognostic role of annexin A2 in multiple myeloma

    Article • Blood, June 2012, American Society of Hematology

    Dr Jerome Moreaux

  101. Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells

    Article • Blood Cells Molecules and Diseases, April 2012, Elsevier

    Dr Jerome Moreaux

  102. New prognostic markers, determined using gene expression analyses, reveal two distinct subtypes of chronic myelomonocytic leukaemia patients

    Article • British Journal of Haematology, March 2012, Wiley

    Dr Jerome Moreaux

  103. Efficient transduction of healthy and malignant plasma cells by lentiviral vectors pseudotyped with measles virus glycoproteins

    Article • Leukemia, February 2012, Springer Science + Business Media

    Dr Jerome Moreaux

  104. Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma

    Article • Haematologica, November 2011, Ferrata Storti Foundation (Haematologica)

    Dr Brian A Walker, Dr Jerome Moreaux

  105. SULFs in human neoplasia: implication as progression and prognosis factors

    Article • Journal of Translational Medicine, January 2011, Springer Science + Business Media

    Dr Jerome Moreaux

  106. The role of fluorescence in situ hybridization and gene expression profiling in myeloma risk stratification

    Article • Srpski arhiv za celokupno lekarstvo, January 2011, National Library of Serbia

    Dr Jerome Moreaux

  107. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines

    Article • Haematologica, December 2010, Ferrata Storti Foundation (Haematologica)

    Dr Jerome Moreaux

  108. MYEOV is a prognostic factor in multiple myeloma

    Article • Experimental Hematology, December 2010, Elsevier

    Dr Jerome Moreaux

  109. Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration

    Article • Blood, November 2010, American Society of Hematology

    Dr Jerome Moreaux

  110. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma

    Article • Haematologica, September 2010, Ferrata Storti Foundation (Haematologica)

    Dr Jerome Moreaux

  111. Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays

    Article • BMC Cancer, May 2010, Springer Science + Business Media

    Dr Jerome Moreaux

  112. Abstract 124: Involvement of the notch pathway in the clonogenicity of human multiple myeloma cell lines

    Article • Cancer Research, April 2010, American Association for Cancer Research (AACR)

    Dr Jerome Moreaux

  113. NPM1 is overexpressed in hyperdiploid multiple myeloma due to a gain of chromosome 5 but is not delocalized to the cytoplasm

    Article • Genes Chromosomes and Cancer, January 2010, Wiley

    Dr Jerome Moreaux

  114. Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study

    Article • British Journal of Cancer, September 2009, Springer Science + Business Media

    Dr Jerome Moreaux

  115. Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis

    Article • Oncogene, August 2009, Springer Science + Business Media

    Dr Jerome Moreaux, Pr John DE VOS

  116. APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop

    Article • European Journal Of Haematology, August 2009, Wiley

    Dr Jerome Moreaux

  117. Embryonic stem cell markers expression in cancers

    Article • Biochemical and Biophysical Research Communications, May 2009, Elsevier

    Dr Jerome Moreaux, Pr John DE VOS

  118. Induction of angiogenesis by normal and malignant plasma cells

    Article • Blood, March 2009, American Society of Hematology

    Dr Jerome Moreaux, Pr John DE VOS

  119. APRIL is overexpressed in cancer: link with tumor progression

    Article • BMC Cancer, March 2009, Springer Science + Business Media

    Dr Jerome Moreaux, Pr John DE VOS

  120. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor

    Article • Blood, February 2009, American Society of Hematology

    Dr Jerome Moreaux

  121. MMSET is overexpressed in cancers: Link with tumor aggressiveness

    Article • Biochemical and Biophysical Research Communications, February 2009, Elsevier

    Dr Jerome Moreaux

  122. Cytokine Pathways in Myeloma Growth and Survival

    Article • Clinical Lymphoma & Myeloma, February 2009, Elsevier

    Dr Jerome Moreaux

  123. Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma

    Article • Blood, January 2009, American Society of Hematology

    Dr Jerome Moreaux, Pr John DE VOS

  124. CD200: A putative therapeutic target in cancer

    Article • Biochemical and Biophysical Research Communications, February 2008, Elsevier

    Dr Jerome Moreaux, Pr John DE VOS

  125. Input of DNA Microarrays to Identify Novel Mechanisms in Multiple Myeloma Biology and Therapeutic Applications

    Article • Clinical Cancer Research, December 2007, American Association for Cancer Research (AACR)

    Dr Jerome Moreaux, Pr John DE VOS

  126. Targeting NF-κB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth

    Article • British Journal of Haematology, July 2007, Wiley

    Dr Jerome Moreaux, Pr John DE VOS

  127. TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines

    Article • Haematologica, June 2007, Ferrata Storti Foundation (Haematologica)

    Dr Jerome Moreaux, Pr John DE VOS

  128. CD200 is a new prognostic factor in multiple myeloma

    Article • Blood, December 2006, American Society of Hematology

    Dr Jerome Moreaux, Pr John DE VOS

  129. P20. TACI-signalling in multiple myeloma – From the identification as potential therapeutic target by gene expression analysis and functional testing to clinical trials

    Article • European Journal of Cancer Supplements, June 2006, Elsevier

    Dr Jerome Moreaux

  130. P43. ErbB-signalling in multiple myeloma – From the identification as potential therapeutic target by gene expression analysis and functional testing to clinical trials

    Article • European Journal of Cancer Supplements, June 2006, Elsevier

    Dr Jerome Moreaux

  131. P21. A molecular classification of multiple myeloma (MM) based on gene expression profiling and fluorescence in situ hybridisation as independent prognostic factor for event free survival (EFS)

    Article • European Journal of Cancer Supplements, June 2006, Elsevier

    Dr Jerome Moreaux

  132. Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma

    Article • Oncogene, May 2006, Springer Science + Business Media

    Dr Jerome Moreaux, Pr John DE VOS

  133. Microarray-based understanding of normal and malignant plasma cells

    Article • Immunological Reviews, April 2006, Wiley

    Dr Jerome Moreaux, Pr John DE VOS

  134. Lymphocytes of dogs immunised with purified excreted-secreted antigens of Leishmania infantum co-incubated with Leishmania infected macrophages produce IFN gamma resulting in nitric oxide-mediated amastigote apoptosis

    Article • Veterinary Immunology and Immunopathology, July 2005, Elsevier

    Dr Jerome Moreaux

  135. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature

    Article • Blood, April 2005, American Society of Hematology

    Dr Jerome Moreaux, Pr John DE VOS

  136. Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells

    Article • Oncogene, February 2005, Springer Science + Business Media

    Dr Jerome Moreaux, Pr John DE VOS

  137. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone

    Article • Blood, April 2004, American Society of Hematology

    Dr Jerome Moreaux

  138. Survival and Proliferation Factors of Normal and Malignant Plasma Cells

    Article • International Journal of Hematology, August 2003, Springer Science + Business Media

    Dr Jerome Moreaux, Pr John DE VOS